The DOI matches its Crossref record.
Long‐term responses in patients with recurring or refractory B‐cell non‐Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan
Abstract
BACKGROUND.: Radioimmunotherapy with radiolabeled monoclonal antibodies to CD20 produces a high response rate in patients with recurring non‐Hodgkin lymphoma (NHL), but the durability of those remissions is not well defined. METHODS.: Data on patients with recurring NHL treated with yttrium Y 90 ibritumomab tiuxetan in 4 clinical trials were reviewed to identify patients with a long‐term response, defined as a time to progression of 12 months or longer. RESULTS.: Long‐term responses were seen in 37% (78/211) of patients. At a median follow‐up of 53.5 months (range, 12.7–88.9) the median duration of response was 28.1 months and the median time to progression was 29.3 months. A third of these patients had been treated with at least 3 previous therapies, and 37% of them had not responded to their last therapy. The findings in patients with follicular lymphoma (n = 59) were similar to those in the overall population of long‐term responders. The estimated overall survival at 5 years was 53% for all patients treated with 90 Y ibritumomab tiuxetan and 81% for long‐term responders. CONCLUSIONS.: A single dose of 90 Y ibritumomab tiuxetan can produce durable responses and prolonged overall survival in a substantial number of patients in whom previous therapies have failed. Cancer 2007. © 2007 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The safety and side effects of monoclonal antibodies
Hansel, T. T., Kropshofer, H., Singer, T., Mitchell, J. A., & George, A. J. T. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3003 · Cited by 1,144
Follicular lymphoma: 2020 update on diagnosis and management
Freedman, A., & Jacobsen, E. (2020) · American Journal of Hematology · doi:10.1002/ajh.25696 · Cited by 268
Sharkey, R. M., Karacay, H., Litwin, S., Rossi, E. A., McBride, W. J., Chang, C.-H., & Goldenberg, D. M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0037 · Cited by 75
Baechler, S., Hobbs, R. F., Jacene, H. A., Bochud, F. O., Wahl, R. L., & Sgouros, G. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.079947 · Cited by 36
Metadata
- Authors
- Witzig, T. E., Molina, A., Gordon, L. I., Emmanouilides, C., Schilder, R. J., Flinn, I. W., Darif, M., Macklis, R., Vo, K., & Wiseman, G. A.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2007-04-18
- Volume
- 109
- Issue
- 9
- Pages
- 1804-1810
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2092966704
- Cited by
- 176
- References
- 0
- FWCI
- 14.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long‐term responses in patients with recurring or refractory B‐cell non‐Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. https://app.cochat.ai/papers/10.1002/cncr.22617
- The paper
- Witzig, T. E., Molina, A., Gordon, L. I., Emmanouilides, C., Schilder, R. J., Flinn, I. W., Darif, M., Macklis, R., Vo, K., & Wiseman, G. A. (2007). Long‐term responses in patients with recurring or refractory B‐cell non‐Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer. https://doi.org/10.1002/cncr.22617
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.